SELLAS Life Sciences (SLS) Cash from Operations (2010 - 2026)
SELLAS Life Sciences (SLS) reported Cash from Operations of 8800000.0 for Q1 2026, up 2.98% year-over-year from 8545610.28 in Q1 2025, and down 79.59% on a QoQ basis from 4900000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Cash from Operations data on file, last reported at 8800000.0 in Q1 2026.
- Quarterly Cash from Operations rose 2.98% year-over-year to 8800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28130000.0 (up 16.56% YoY) and the FY2025 annual result came in at 28400000.0, up 19.78% from the prior year.
- Cash from Operations eased to 8800000.0 in Q1 2026 per SLS's latest filing, from 4900000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 4825000.0 in Q4 2023 and bottomed at 12127000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 7153000.0 (2024), against an average of 7518882.35.
- The widest annual swing landed in 2023, when Cash from Operations slumped 69.61%; it then soared 31.5% in 2025.
- Tracing SLS's Cash from Operations over 5 years: stood at 5152000.0 in 2022, then rose by 6.35% to 4825000.0 in 2023, then slumped by 48.25% to 7153000.0 in 2024, then surged by 31.5% to 4900000.0 in 2025, then slumped by 79.59% to 8800000.0 in 2026.
- Per Business Quant, the three latest SLS Cash from Operations figures stand at 8800000.0 (Q1 2026), 4900000.0 (Q4 2025), and 7100000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.80 Mn |
| Mar 31, 2026 | -8.80 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Dec 31, 2025 | -4.90 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Sep 30, 2025 | -7.10 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Jun 30, 2025 | -7.33 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Mar 31, 2025 | -9.07 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Dec 31, 2024 | -7.15 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Sep 30, 2024 | -7.81 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Jun 30, 2024 | -9.68 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Dec 31, 2023 | -4.83 Mn |
| Sep 30, 2023 | -6.89 Mn |
| Sep 30, 2023 | -6.89 Mn |
| Jun 30, 2023 | -7.57 Mn |
| Jun 30, 2023 | -7.57 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Dec 31, 2022 | -5.15 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Sep 30, 2022 | -5.75 Mn |
| Jun 30, 2022 | -5.76 Mn |
| Jun 30, 2022 | -5.76 Mn |
| Mar 31, 2022 | -7.15 Mn |
| Mar 31, 2022 | -7.15 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Dec 31, 2021 | -4.98 Mn |
| Sep 30, 2021 | -5.88 Mn |
| Sep 30, 2021 | -5.88 Mn |
| Jun 30, 2021 | -4.90 Mn |
| Jun 30, 2021 | -4.90 Mn |
| Mar 31, 2021 | -10.27 Mn |
| Mar 31, 2021 | -10.27 Mn |
| Dec 31, 2020 | 3.42 Mn |
| Dec 31, 2020 | 3.42 Mn |
| Sep 30, 2020 | -3.63 Mn |
| Sep 30, 2020 | -3.63 Mn |
| Jun 30, 2020 | -3.38 Mn |
| Jun 30, 2020 | -3.38 Mn |
| Mar 31, 2020 | -6.83 Mn |
| Mar 31, 2020 | -6.83 Mn |
| Dec 31, 2019 | -4.18 Mn |
| Dec 31, 2019 | -4.18 Mn |
| Sep 30, 2019 | -3.82 Mn |
| Sep 30, 2019 | -3.82 Mn |
| Jun 30, 2019 | -4.66 Mn |
| Jun 30, 2019 | -4.66 Mn |
| Mar 31, 2019 | -4.99 Mn |
| Mar 31, 2019 | -4.99 Mn |
| Dec 31, 2018 | -4.56 Mn |
| Dec 31, 2018 | -4.56 Mn |
| Sep 30, 2018 | -14.17 Mn |
| Sep 30, 2018 | -14.17 Mn |
| Jun 30, 2018 | -6.30 Mn |
| Jun 30, 2018 | -6.30 Mn |
| Mar 31, 2018 | -5.40 Mn |
| Mar 31, 2018 | -5.40 Mn |
| Dec 31, 2017 | -1.74 Mn |
| Dec 31, 2017 | -1.74 Mn |
| Sep 30, 2017 | -2.40 Mn |
| Sep 30, 2017 | -2.40 Mn |
| Jun 30, 2017 | -3.05 Mn |
| Jun 30, 2017 | -3.05 Mn |
| Mar 31, 2017 | -3.80 Mn |
| Mar 31, 2017 | -3.80 Mn |
| Dec 31, 2016 | 15.91 Mn |
| Dec 31, 2016 | 15.91 Mn |
| Sep 30, 2016 | -10.17 Mn |
| Sep 30, 2016 | -10.17 Mn |
| Jun 30, 2016 | -7.85 Mn |
| Jun 30, 2016 | -7.85 Mn |
| Mar 31, 2016 | -9.74 Mn |
| Mar 31, 2016 | -9.74 Mn |
| Dec 31, 2015 | -5.93 Mn |
| Dec 31, 2015 | -5.93 Mn |
| Sep 30, 2015 | -13.44 Mn |
| Sep 30, 2015 | -13.44 Mn |
| Jun 30, 2015 | -8.94 Mn |
| Jun 30, 2015 | -8.94 Mn |
| Mar 31, 2015 | -10.50 Mn |
| Mar 31, 2015 | -10.50 Mn |
| Dec 31, 2014 | -8.29 Mn |
| Dec 31, 2014 | -8.29 Mn |
| Sep 30, 2014 | -7.72 Mn |
| Sep 30, 2014 | -7.72 Mn |
| Jun 30, 2014 | -12.97 Mn |
| Jun 30, 2014 | -12.97 Mn |
| Mar 31, 2014 | -8.05 Mn |
| Mar 31, 2014 | -8.05 Mn |
| Dec 31, 2013 | -2.84 Mn |
| Dec 31, 2013 | -2.84 Mn |
| Sep 30, 2013 | -7.98 Mn |
| Sep 30, 2013 | -7.98 Mn |
| Jun 30, 2013 | -7.12 Mn |
| Jun 30, 2013 | -7.12 Mn |
| Mar 31, 2013 | -5.33 Mn |
| Mar 31, 2013 | -5.33 Mn |
| Dec 31, 2012 | -5.18 Mn |
| Dec 31, 2012 | -5.18 Mn |
| Sep 30, 2012 | -4.17 Mn |
| Sep 30, 2012 | -4.17 Mn |
| Jun 30, 2012 | -6.75 Mn |
| Jun 30, 2012 | -6.75 Mn |
| Mar 31, 2012 | -4.89 Mn |
| Mar 31, 2012 | -4.89 Mn |
| Dec 31, 2011 | -4.17 Mn |
| Dec 31, 2011 | -4.17 Mn |
| Sep 30, 2011 | -3.41 Mn |
| Sep 30, 2011 | -3.41 Mn |
| Jun 30, 2011 | -4.06 Mn |
| Jun 30, 2011 | -4.06 Mn |
| Mar 31, 2011 | -3.03 Mn |
| Mar 31, 2011 | -3.03 Mn |
| Dec 31, 2010 | -1.87 Mn |
| Dec 31, 2010 | -1.87 Mn |
| Sep 30, 2010 | -2.24 Mn |
| Sep 30, 2010 | -2.24 Mn |